Panel to Review Novo Nordisk’s Insulin Icodec

Federal Register notice: FDA schedules a 5/24 Endocrinologic and Metabolic Drugs Advisory Committee meeting to discuss the safety and efficacy of a Novo Nordisk BLA for NNC0148–0287 for injection (insulin icodec), a long-acting insulin analog product. The proposed indication is to improve glycemic control in adults with diabetes mellitus. To view the notice, click here.

Read more